Genmab (GMAB) said Wednesday that worldwide net trade sales of its cancer drug Darzalex, including sales of the subcutaneous product Darzalex Faspro, totaled $4.21 billion in Q2.

Sales of the drug totaled $2.44 billion in the US and $1.77 billion in the rest of the world, the company said.

Genmab receives royalties on net sales of Darzalex under an exclusive worldwide license to Johnson & Johnson (JNJ), the company said.